(HGD), or EA, drawn from two well-annotated epidemiologic parent studies. Results Multiple metabolites differed significantly (P < 0.05) between BE versus GERD (n = 9), and between HGD/EA versus BE (n = 4). Several top candidates (FDR q ≤ 0.15), including urate, homocysteine, and 3-nitrotyrosine, are linked to inflammatory processes, which may contribute to BE/EA pathogenesis. Multivariate modeling achieved moderate discrimination between HGD/EA and BE (AUC = 0.75), with less pronounced separation for BE versus GERD (AUC = 0.64). Conclusion Serum metabolite differences can be detected between individuals with GERD versus BE, and between those with BE versus HGD/EA, and may help differentiate patients at different stages of progression to EA.
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23 Page 2 of 11 treat them before they develop invasive cancer. However, 95% of BE patients will never progress to cancer, while only ~5% of EA cases are diagnosed as a result of screening and surveillance. Upper endoscopy with biopsy, the standard method of diagnosing and monitoring BE, is both invasive and expensive, and its frequent yet variable implementation has not appreciably increased early detection or decreased EA mortality (Vaughan and Fitzgerald 2015) . Development of new and non-invasive methods for stratification and assessment of patients at risk of EA would address important unmet clinical needs (Vaughan and Fitzgerald 2015; Reid et al. 2010) .
Metabolomics has emerged as a promising domain for identifying molecular signatures associated with cancer (Asiago et al. 2010; Denkert et al. 2006; Mayers 2014; Slupsky et al. 2010; Sreekumar et al. 2009; Wikoff et al. 2015) . In contrast to genomics, transcriptomics, or proteomics, metabolomics describes the study of concentrations and fluxes of low-molecular-weight metabolites present in biofluids or tissue (Gowda et al. 2008; Nicholson et al. 1999) . As metabolic fluctuations lie downstream of alterations at the DNA, RNA, and protein level, metabolomics offers a sensitive and comprehensive functional read-out of biological systems. Metabolite levels and metabolic pathways are significantly altered in a broad spectrum of human cancers (Gu et al. 2012; Liesenfeld et al. 2013; O'Connell 2012; Spratlin et al. 2009 ). Adaptive changes such as increased rates of aerobic glycolysis (the Warburg effect), amino acid metabolism, and lipid turnover are thought to be important features of the neoplastic process that facilitate sustained cellular proliferation and tumor expansion (O'Connell 2012; Spratlin et al. 2009) .
Several past metabolomics studies, generally of modest sample size, have focused on esophageal adenocarcinoma (Dave et al. 2004; Davis et al. 2012; Djukovic et al. 2010; Doran et al. 2003; Sanchez-Espiridion et al. 2015; Suzuki et al. 2014; Yakoub et al. 2010; Zhang et al. 2012 Zhang et al. , 2011 . In one of the earlier reports, 1 H magic angle spinning-nuclear magnetic resonance (NMR) spectroscopy-based profiling of intact esophageal tissue samples identified a panel of metabolites that separated control tissues from tumor tissues and proximal histologically normal mucosa from individuals with EA (Yakoub et al. 2010) . In a second study, Raftery and colleagues conducted a targeted mass-spectrometry (MS)-based analysis of eight nucleosides in serum samples from EA cases or healthy controls, and identified five as differentially abundant (Djukovic et al. 2010) . Serum metabolites identified using NMR and LC-MS were combined to generate a signature capable of accurately discriminating between EA patients and healthy controls (Zhang et al. 2012) . Urinary metabolite panels identified by 1 H NMR spectroscopy have also facilitated separation of healthy controls from patients with BE or those with EA or esophageal squamous cell carcinoma (ESCC) (Davis et al. 2012) . Most recently, serum levels of the amino acid L-proline, ketone body 3-hydroxybutyrate, and carbohydrate D-mannose were found to differ between EA cases versus healthy controls (Sanchez-Espiridion et al. 2015) . Analyses in cell lines and isolated tissues specimens have described alterations in both energy metabolism and metabolicallyrelevant gene expression patterns across the disease continuum from BE to EA (Phelan et al. 2014; Suchorolski et al. 2013) . Collectively, while this overall body of work has suggested that metabolic perturbations are associated with BE/EA, very limited agreement between studies has been observed with respect to specific metabolite alterations, likely reflecting significant heterogeneity in study design, sample collection/processing, analytic platforms, and statistical approaches, as well as the confounding effects of modifying factors (age, race, smoking, etc) .
In this discovery study, we used an optimized LC-MS targeted profiling platform to screen for differentially abundant serum metabolites among individuals with (1) BE versus GERD, and (2) HGD/early-stage EA versus BE. We thus focused on clinically-relevant comparisons, rather than analyzing readily distinguishable groups such as cancer cases and healthy controls. A total of 322 serum samples (100 GERD, 122 BE, 100 HGD/EA) were selected from two prior epidemiologic studies of BE and EA and subjected to targeted metabolomic analysis of 57 metabolites, which collectively encompass several major metabolic pathways (glycolysis/TCA cycle, amino acid, nucleotide, and fatty acid metabolism). The potential utility of derived metabolite profiles to discriminate between these disease states was investigated through construction and evaluation of multivariate classification models.
Materials and methods

Study design
Participants in this study were selected from individuals enrolled in one of two independent parent studies: (1) a community clinic-based case-control study among patients with GERD (Study of Reflux Disease, SRD) (Edelstein et al. 2009 (Edelstein et al. , 2007 , and (2) a prospective longitudinal cohort study of BE patients (Seattle BE Project, SBEP) (Galipeau et al. 2007) . Briefly, subjects from the SRD were residents of western Washington without a previous diagnosis of BE who underwent a baseline endoscopy for the investigation of chronic GERD symptoms. Participants with specialized intestinal metaplasia were classified as cases, and a subset with visible evidence of columnar epithelium were further classified as BE cases (Edelstein et al. 2007; Sampliner 2002) . GERD controls consisted of a ~50% random sample of subjects who were biopsy-negative for specialized intestinal metaplasia. The SBEP includes >400 BE patients who underwent periodic endoscopic surveillance with biopsy according to the Seattle Protocol (Reid et al. 2003) . Diagnosis of dysplasia or EA, and/or confirmation of existing BE, was conducted by a single pathologist based on histologic assessment of biopsy specimens according to standard guidelines. Demographic and lifestyle characteristics were ascertained in both studies via similar structured interviews, either 1-2 months after endoscopy (SRD), or at baseline and follow-up endoscopy visits (SBEP).
The present study included a total of 322 participants: 162 individuals from the SRD (100 GERD cases and 62 BE cases), and 160 individuals from the SBEP (60 BE cases and 100 cases of high-grade dysplasia (HGD) or earlystage EA) ( Figure S1 ). The BE case group from each study included an approximately equal number of long-segment BE (≥3 cm) and short-segment BE (<3 cm) cases. Participation was restricted to white subjects of age ≥20 years. Exclusions were made for GERD cases with visible evidence of columnar mucosa on endoscopy, and for EA cases with Stage II disease or higher. Cases were frequency balanced by age and sex across case type, within study, where feasible. This study was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center.
Serum specimens
Blood samples from study participants selected for the present analyses were obtained within 0-120 days (median: 45.5 days) following endoscopy (SRD), or at one of the periodically-scheduled endoscopy visits during follow-up (SBEP). Among the SBEP BE subjects, blood samples were selected from the last available endoscopy visit at which the maximum histologic diagnosis was non-dysplastic BE. Among the combined HGD/EA case group, blood specimens were selected from an endoscopy visit at the time of EA diagnosis (n = 22), shortly before a subsequent recorded EA diagnosis (n = 17), or from the last available endoscopy date at which HGD was detected (n = 61) (Table S1 ). Blood samples were allowed to clot for 45 min, centrifuged at 4 °C for 10 min at 1300xg, and the resulting sera were separated and aliquoted into separate tubes and frozen at −80 °C. All specimens were processed and frozen for long-term storage within 4 h post-draw. Each sample was assigned a unique laboratory identification number, which specified the order of processing and blinded laboratory personnel to sample identities. Samples of each case type were equally represented and randomly ordered within batch. Specimens were delivered on dry ice to the Northwest Metabolomics Research Center and stored at −80 °C until use.
Laboratory methods
Frozen patient sera were thawed at room temperature for 30 min. Detailed protocols for sample preparation have been published previously (Zhu et al. 2014) . Two sample injections (2 and 10 μL) were used for LC-MS/MS analysis in positive and negative modes, respectively.
13 C-lactate and 13 C-tyrosine were added to each serum sample, after deproteinization, to monitor the system performance. Replicates of quality control serum samples were injected into the LC-MS/MS after every ~10 study samples, and derived profiles were used to calculate the coefficient of variation (CV) for each metabolite.
A robust targeted LC-MS/MS method has been developed and used in multiple studies in the Northwest Metabolomics Research Center (NW-MRC) (Zhu et al. 2014; Carroll et al. 2015; Sperber et al. 2015) . Briefly, LC-MS/MS profiling was performed on an Agilent 1260 LC (Agilent Technologies, Santa Clara, CA) AB Sciex QTrap 5500 MS (AB Sciex, Toronto, Canada) system. MRM transitions were monitored in negative and positive mode, and extracted MRM peaks were integrated using MultiQuant 2.1 software (AB Sciex, Toronto, Canada).
Data processing and statistical analysis
Peak intensities were integrated using Analyst 1.5 software (AB Sciex), and resulting integrals were used for further analyses. Profiled analytes were excluded if detectable signal was absent in >33% of all study samples, or if the CV across all QC samples exceeded 20%. Measurements for an individual metabolite were normalized to the mean signal within-batch for that metabolite and log 2 -transformed. To evaluate relative differences in mean metabolite signals between case types, linear regression analyses were conducted in which metabolite values were regressed on case status (X, defined as 0/1), with adjustment for covariates (C i ) : M ~ α 0 + [α 1 C 1 + ... + α n C n ] + β X. Metabolites for which β differed significantly from zero (at P < 0.05) were identified as preliminary candidates. Multiple comparisons were accounted for using the Benjamini-Hochberg false discovery rate (FDR) (Glickman et al. 2014) .
Two case type comparisons were examined: (1) BE versus GERD (SRD samples), and (2) HGD/EA versus BE (SBEP samples). Inclusion of an individual covariate (C i ) in a given regression model was determined by assessment of the association between values of the metabolite and the covariate in samples of the reference case type (1: GERD and 2: BE) : M ~ α + γ i C i | X = 0. Covariates for which γ i differed significantly from zero (at P < 0.05) were included in the primary regression model for the selected metabolite. Adjustment was considered for several variables considered risk factors for BE or EA-age (grouped-linear: 20-39, 40-49, 50-59, 60-69, 70-79, 80+ years) , sex (male/ female), smoking history (yes/no), and waist-to-hip-ratio (WHR, <0.9 or ≥0.9, males; <0.8 or ≥0.8, females)-and for duration of specimen storage at −80 °C (grouped-linear: 0-4, 5-9, 10-14, or 15-19 years). We adopted this approach to provide reasonable control for likely confounding factors while avoiding potentially biased inference from overadjustment. Fold changes in geometric mean metabolite signals between case groups were calculated using covariate-adjusted metabolite values. For a given metabolite, if covariates C 1 and C 2 were included in the main regression model, adjusted metabolite values were obtained as follows: M adj = M unadj −δ 1 C 1 −δ 2 C 2 , where δ 1 and δ 2 are coefficients derived from the regression M ~ α + δ 1 C 1 + δ 2 C 2 | X = 0.
For multivariate modeling, we first selected the top pool of candidates for each comparison based on a P-value threshold of 0.05 (n = 9 metabolites for BE versus GERD, and n = 4 metabolites for HGD/EA versus BE). Models for disease classification were constructed using regularized logistic regression with elastic net penalty (R package: glmnet) (Friedman et al. 2010) . Equal numbers of cases and controls were randomly allocated to a training set (75%), used for variable selection and model selection, or a testing set (25%), used for (preliminary) model validation.
With the mixing parameter (∝) set to 0.5, fivefold crossvalidation was conducted within the training set only to select the optimal value of the penalty parameter (λ). Based on this value of λ, a model was generated using the complete training set data and used to predict class values for subjects in the testing set. Monte Carlo cross validation (MCCV) was conducted, such that the entire procedure described was repeated using 100 different training (and associated testing) sets randomly selected from the study sample. Mean estimated area under the receiver-operating curve (AUC) was calculated across the 100 testing sets. Composite average ROC curves were constructed to summarize overall classification accuracy (R package: ROCR) (Sing et al. 2005) . All univariate statistical analyses were conducted using Stata v13.1 (College Station, TX), while multivariate modeling was conducted using R v3.03.
Results
Study participant characteristics
Demographic and behavioral characteristics of included participants are shown in Table 1 . Study participation (Table S2) . At the nominal significance threshold of P < 0.05, a number of metabolites were found to differ in mean signal intensity among individuals with BE versus GERD (n = 9), and HGD/EA versus BE (n = 4) ( Fig. 1 . In exploratory subgroup analyses, urate also remained highly significant (P = 0.001, q = 0.058) when the HGD/EA case group of 100 participants was restricted to the 22 included EA cases with blood specimens drawn at the time of cancer diagnosis (data not shown). 
Multivariate disease classification models
To investigate the utility of combining multiple serum metabolites into a signature to discriminate between the indicated case types, we conducted multivariate modeling using regularized logistic regression with elastic net penalty. The mean AUC of models built using the top nine metabolites (P < 0.05) selected for BE versus GERD, and assessed across 100 rounds of MCCV, was 0.64 (SD = 0.08); the mean AUC of models built using the top four metabolites (P < 0.05) selected for HGD/EA versus BE was 0.75 (SD = 0.07) (Fig. 2) . Several individual metabolite variables were retained in ≥80% of all MCCV iterations for the BE versus GERD classifier (n = 5 of 9), and for the HGD/EA versus BE classifier (n = 4 of 4) ( Table S4) . For each comparison, the metabolite retained in the highest percentage of MCCV iterations (models) was also the metabolite with the lowest P value in our primary linear regression analyses (creatine and urate, respectively).
Discussion
The prevention and control of EA has become an increasingly important public health challenge, as incidence of this rare but lethal cancer has risen eightfold in recent decades (Vaughan and Fitzgerald 2015) . Despite identification of an epithelial precursor lesion and several strong epidemiologic risk factors, current screening and surveillance efforts, based largely on upper endoscopy with biopsy of patients with GERD or BE, have not significantly improved early detection or lowered EA mortality (Vaughan and Fitzgerald 2015; Reid et al. 2010 ). An important unmet need remains the development of robust non-invasive methods of assessing and stratifying at-risk patients according to their level of current, and risk of future, disease progression (Vaughan 2014) . Here, we adopted metabolomics profiling methods to identify serum metabolites correlated with distinct disease intermediates along the pathway to EA. Targeted interrogation of 57 serum metabolites encompassing several major metabolic pathways revealed multiple metabolites that differed in abundance when comparing patients with BE versus GERD, and HGD/EA versus BE. Multivariate models based on candidate metabolite markers yielded moderate discrimination between the HGD/EA and BE case groups, with lesser separation observed for BE versus GERD.
Despite a large number of cancer metabolomics studies in recent years, relatively few have focused on EA (or BE). These mostly small-scale investigations employed various NMR-or MS-based methods to conduct either targeted or global metabolite profiling in tissue, serum, or urine (Dave et al. 2004; Davis et al. 2012; Djukovic et al. 2010; Doran et al. 2003; Sanchez-Espiridion et al. 2015; Suzuki et al. 2014; Yakoub et al. 2010; Zhang et al. 2012 Zhang et al. , 2011 . Considerable variability has been observed among reported findings, likely reflecting significant differences not only in analytic platforms and types of biospecimens, but also in study design, subject selection, and sample preparation (Abbassi-Ghadi et al. 2013) . Differentially abundant metabolites identified by NMR in EA tissue relative to normal tissue have included phosphocholine, glutamate, myo-inositol, adenosine-containing compounds, uracil, and inosine (Yakoub et al. 2010) . Studies comparing serum from EA patients versus healthy controls, using either MS or NMR, have described differences in multiple nucleosides, amino acids, and other metabolites (Djukovic et al. 2010; Sanchez-Espiridion et al. 2015; Zhang et al. 2012 Zhang et al. , 2011 . NMR profiling of urine from healthy controls or EA/ESCC patients has identified differences in sucrose, pantothenate, urea, methanol, pyroglutamate, hypoxanthine, fucose, 2-aminobutyrate, and cis-aconitate (Davis et al. 2012 ). In total, minimal consensus has emerged regarding consistent metabolite-based signatures of EA, and our biological understanding of the inter-relationships between metabolite levels in tissues, blood, and urine remains limited. Furthermore, no previous studies have included at-risk GERD patients as a comparison group.
The individual metabolite marker candidates identified in our analysis belong to several classes of compounds. The nine metabolites differentiating BE from GERD (P < 0.05) included seven amino acids or amino acid derivatives (creatine, homocysteine, 3-nitrotyrosine, hydroxyproline/aminolevulinate, arginine, tyrosine, ornithine), one fatty acid (linoleic acid), and one sugar alcohol (sorbitol). The four metabolites differentiating HGD/EA from BE (P < 0.05) included one nucleotide derivative (urate), two amino acid derivatives (taurine and xanthurenate), and one sugar (erythrose). On a statistical level, the most significant signal observed was for urate (P = 0.0002, q = 0.01), in the HGD/ EA versus BE comparison, and for creatine and homocysteine (q < 0.15) in the BE versus GERD comparison. Urate also showed non-significant elevation in BE versus GERD (P = 0.12), while homocysteine was similarly non-significantly elevated in HGD/EA versus BE (P = 0.17).
It is of interest to note that several of the top identified metabolites (urate, homocysteine, and 3-nitrotyrosine) have been linked to inflammatory processes (Danese et al. 2005; Fini et al. 2012; Vaninetti et al. 2008) , as local and systemic inflammation are believed to play important roles in the pathogenesis of BE/EA (Reid et al. 2010) . Urate is the mono-anionic form of uric acid, a derivative of purine nucleotides. High levels of circulating uric acid have been associated with a number of medical conditions, including gout, kidney stones, tumor lysis syndrome, metabolic syndrome, and diabetes (Fini et al. 2012) , as well as with increased risk of several cancers (Kolonel et al. 1994; Strasak et al. 2009 ). Originally described as an antioxidant, uric acid has more recently been found to promote inflammation, both in its crystal and soluble forms, through activation of Toll receptors and stimulation of NFκb, respectively (Fini et al. 2012) . The amino acid homocysteine, a derivative of methionine, functions in one-carbon metabolism reactions, which are important for nucleotide synthesis and DNA methylation. Elevated circulating homocysteine has been associated with increased risk of head and neck cancers, colorectal cancer, and colorectal adenoma recurrence (Bobe et al. 2010; Fanidi et al. 2015; Miller et al. 2013) . Homocysteine induces inflammatory cytokine production in cultured human cells, and has been mechanistically linked to inflammatory bowel disease (IBD) and atherosclerosis (Danese et al. 2005; Zhou and Austin 2009) . Nitrotyrosine (NT) is derived from nitration of the amino acid tyrosine, mediated by reactive oxygen species such as peroxynitrite anion. NT is considered a marker of oxidative stress, inflammation, and protein damage, and has been detected in a number of disease states such as gastritis and IBD (Vaninetti et al. 2008) . Past studies have also described elevated NT immunoreactivity in esophageal tissue specimens from patients with BE (Vaninetti et al. 2008; Jiménez et al. 2005) and EA (Vaninetti et al. 2008; Allameh et al. 2009) , and in the esophagus of an animal model of EA (Goldstein et al. 1998) .
Local and systemic inflammation represent plausible drivers of altered metabolite levels, as do increased rates of local cell proliferation associated with cancer precursors and early lesions. Metabolite alterations observed across case types may or may not reflect underlying metabolite changes within the esophageal epithelium itself. Interrogation of paired tissue biopsies from the same individuals and time points in which serum specimens were isolated will be required to address this uncertainty and facilitate accurate biological interpretation of the reported metabolite differences.
Non-invasive clinical assessment tools for patients at risk of EA could be of use in at least two clinical scenarios: (1) initial evaluation of patients with severe or chronic GERD symptoms, to identify those most likely to have BE (or advanced pathology); and (2) additional monitoring of BE patients between surveillance endoscopies, to identify those most likely to have HGD or early-stage EA. Preliminary risk models for BE or EA based on classic epidemiologic risk factors such as age, sex, BMI/WHR, smoking status, and GERD symptoms (Rubenstein et al. 2013; Thrift et al. 2012a, b; Xie and Lagergren 2016) have provided a promising starting point for improved risk stratification tools, but the modest classification accuracy of most models requires improvement to afford significant clinical utility. One emerging approach for enhancing non-invasive risk assessment is the Cytosponge, a cytological sampling device that yields esophageal epithelial cells for immunostaining or molecular analyses (Ross-Innes et al. 2015; Weaver et al. 2014) . Our results suggest that the serum metabolome may represent another viable source of clinical information, and point to the potential utility of integrating novel candidate biomarkers with existing classical models to build more robust classifiers. Given that existing tissuebased variables such as dysplasia grade, DNA content flow cytometry, and somatic chromosome abnormalities provide strong discrimination among BE patients (Li 2015) , serumbased assays will require substantial improvements to have direct clinical application. Future studies are also needed to probe whether serum metabolite signatures are specific to BE or HGD/EA, or may correlate with other conditions prevalent in a larger sample of at-risk individuals.
This discovery study had a number of key strengths. First, in contrast to past reports that primarily used healthy normal controls, our analysis focused on comparisons most relevant to clinical decision making and targeted risk assessment: BE versus GERD, and HGD/EA versus BE. Second, GERD, BE, and HGD/EA were all diagnosed according to standard definitions based on endoscopic and histopathologic evaluation, and serum specimens were processed according to uniform procedures and frozen at −80 °C within 4 h for long-term storage. Third, biospecimens were linked with extensive epidemiologic and clinical data from high-quality studies of BE and EA. Statistical analyses were adjusted as needed for a number of potential confounders, including age, sex, smoking, and waist-tohip ratio. Fourth, to avoid capturing metabolite alterations associated exclusively with advanced/incurable disease, EA cases were restricted to Stage 0/1. Finally, our LC-MSbased profiling platform has been optimized for sensitivity and accuracy, and used successfully to identify and/or validate serum metabolite biomarker candidates for a number of diseases (Zhu et al. 2014; Baniasadi et al. 2013 ).
Our study also had several limitations. First, while a total sample size of 322 participants was larger than that used in most previous metabolomics studies of BE/EA, it is nonetheless still relatively small when considering the modest magnitude of disease-associated serum metabolite fluctuations typically observed, coupled with the anticipated degree of natural biologic (and technical) variability in such measurements (Sampson et al. 2013) . Given that participants in the present analysis were drawn from two distinct parent studies (SRD & SBEP), we chose to retain two separate BE case groups and conduct only within-study comparisons (BE versus GERD, and HGD/EA versus BE), to eliminate the potential for confounding by systematic differences between participants/specimens by parent study (e.g. SBEP blood samples were all collected under fasting conditions prior to endoscopy, while SRD samples were collected in the field under non-fasting circumstances). This decision effectively reduced study power by decreasing the size of our BE comparison groups, and precluded a comparison of HGD/EA versus GERD patients. Second, while our targeted LC-MS analysis enabled assessment of 57 metabolites in multiple metabolic pathways, these compounds represent only a very small fraction of the total serum metabolome. The combination of disparate detection technologies, such as MS and NMR, and the pairing of targeted and global profiling approaches, may facilitate identification of a richer set of differentiating metabolites (Zhang et al. 2012) . Exploratory global MS profiling in the present study, however, did not yield strong additional signals (data not shown). Third, while our analyses made use of extensive covariate data on study participants for statistical adjustments, often not conducted in metabolomics reports, the possibility remains for some degree of residual or unmeasured confounding, whereby observed metabolite differences between case types might reflect underlying subject/specimen characteristics. Medications and dietary patterns are two variables capable of influencing metabolite levels (Kim 2014 ), which were not included in our analyses. However, given that we restricted EA cases to stage 0/1 (prior to surgical or chemoradiation treatment) and used refractory GERD cases as our primary "controls" (instead of healthy normals), substantial heterogeneity in medication usage between case groups appears relatively unlikely. It remains uncertain whether significant dietary differences exist between GERD, BE, and HGD/EA patients.
This study provides evidence that intermediate disease states preceding the development of EA correlate with detectable alterations in the serum metabolome. Our results expand upon the findings of a small number of past analyses by identifying metabolite differences across gradations of disease progression (BE versus GERD, and HGD/EA versus BE) that are most relevant to the clinical settings of screening and surveillance. Further studies in larger independent populations will be necessary to validate these results, and ultimately to evaluate the utility of serum metabolite profiles as a novel source of clinical information for improving non-invasive assessment and monitoring of patients at risk of EA.
